Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Research and development - MRTP

Sales, general and administrative

Impairment of intangible assets

Depreciation

Amortization

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

22nd Century Group

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. It focuses on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp or cannabis plants through genetic engineering, gene-editing, and modern plant breeding techniques. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

22nd Century Group advances VLN and GVB units towards profitability

22nd Century Group's Q4 2022 earnings call highlighted progress in VLN tobacco and GVB hemp/cannabis units, with plans for multi-state launches and cash positive operations in 2024. Despite challenges like the Grass Valley facility fire, the company remains focused on achieving profitability through revenue growth and market expansion. Key strengths include successful pilot results, volume growth, and a clear path to cash positivity for both business units.

22nd Century Group (XXII) reports strong Q1 performance and growth strategies

22nd Century Group (XXII) showcases strong performance and strategic initiatives to drive revenue growth and achieve cash positivity by 2024.
Despite challenges such as analyst inquiries and insurance impacts, the company's focus on cost efficiencies and margin improvements positions it for success.
Opportunities in revenue growth, bulk ingredient capacity expansion, and margin enhancements present promising prospects for future profitability and market growth.

22nd Century Group reports strong Q2 performance amidst operational challenges

22nd Century Group's Q2 performance showcased growth in sales but faced challenges in gross profit due to production mix shifts.
The company's proactive strategies for cost savings, brand value creation, and gross margin improvement indicate a focus on long-term sustainability.
Despite challenges like VLN rollout delays and tobacco business hurdles, opportunities in market differentiation and efficiency improvements are being pursued.

22nd Century Group pursues profitability through strategic shifts and cost management

22nd Century Group's Q4 2023 earnings call highlighted efforts to achieve profitability by reducing cash burn, focusing on VLN cigarettes for harm reduction, and exploring CMO opportunities in tobacco manufacturing. Despite challenges like decreased net sales and a negative gross profit, the company aims to reach breakeven by Q1 2025.

22nd Century Group reduces cash burn, aims for profitability by 2025

22nd Century Group's Q1 2024 performance reflects progress towards profitability, with improved financial discipline and operational efficiency.
While facing revenue challenges and legal disputes, the company's strategic initiatives and investor support position it for future growth and success.
The focus on reducing losses, strengthening the balance sheet, and expanding market presence underscores the company's commitment to long-term sustainability.

22nd Century Group reports Q2 financial turnaround and growth strategies

22nd Century Group's Q2 2024 performance reflects a notable financial turnaround and progress towards profitability.
Strategic initiatives, leadership appointments, and product strategies position the company for future growth and success.
While challenges remain in achieving cash positive operations, opportunities in market expansion and product innovation offer avenues for continued advancement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY.

Turnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco Assets Turnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco Assets

22nd Century Appoints Larry Firestone as Chairman and CEO

Calavo Growers

Planet Green Holdings Corp

Spectrum Brands Hlds

Upexi Inc

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 5 Risk Off Stocks Which Could Rescue Your Portfolio This Month - Planet Green Holdings (AMEX:PLAG), Calavo Growers (NASDAQ:CVGW)

Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash Requirements

22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise

Albertsons Companies

The Real Good Food Co

Steakholder Foods Ltd

Top 4 Risk Off Stocks You'll Regret Missing In Q4 - The Real Good Food (NASDAQ:RGF), Albertsons Companies (NYSE:ACI)

BUFFALO, N.Y., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today announced that it has again expanded its VLN® retail presence with more than 500 additional locations across 11 states.

22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores

Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding Capabilities

22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License

BUFFALO, N.Y., Nov. 06, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today reported results for the third quarter ended September 30, 2023, and provided an update on recent business highlights.

22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results

BUFFALO, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, announced that it supports the recent move by the US Food and Drug Administration to send final rules aimed at banning menthol in cigarettes and banning flavored cigars to the White House Office of Management and Budget for review, a key regulatory step toward the rules becoming federal policy.

22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB

37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets 37% Reduction Through the Transfer of Non-Core and Previously Restricted Assets

22nd Century Group (XXII) Reduces Debt by $8.1 Million

BUFFALO, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced the pricing of its previously announced public offering of 10,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 20,000,000 shares of common stock, at a combined public offering price of $0.525 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.525 per share, are immediately exercisable and will expire five years following the date of issuance. The offering is expected to close on or about October 19, 2023, subject to the satisfaction of customary closing conditions.

22nd Century Announces Pricing of $5.25 Million Public Offering

BUFFALO, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that it intends to offer and sell in a “best efforts” public offering shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock. All of the shares of common stock (or common stock equivalents) and warrants in the offering are to be offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

22nd Century Announces Proposed Public Offering

22nd Century Group's (XXII) VLN cigarettes represent a remarkable breakthrough as the first and only combustible cigarettes that the FDA has authorized as Modified Risk Tobacco Products.

22nd Century (XXII) Expands VLN Cigarettes to 1,200 Drug Stores

First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023 First Drug Store Channel Retail Chain Begins VLN® Sales in September, Continues to Book Additional Launches for Rest of 2023

22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States

Altria

Philip Morris

Turning Point Brands

The Zacks Tobacco industry players battle concerns surrounding soft cigarette volumes and high input costs, while pricing power and smoke-free products aid. Philip Morris (PM), Altria Group (MO), Turning Point (TPB) and 22nd Century Group (XXII) look well-placed.

4 Tobacco Stocks Worth Watching Despite Industry Concerns

22nd Century (XXII) is embarking on a strategic journey to unlock the full potential of its tobacco assets. This reflects the company's commitment to delivering long-term value to its shareholders.

22nd Century (XXII) Begins Strategic Review of Tobacco Assets

BUFFALO, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ: XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal advisors, has initiated a process to evaluate strategic alternatives with respect to the Company's tobacco assets. The process will include consideration of a range of strategic, operational and financial transactions and alternatives, such as business combinations, asset sales, licensing agreements, alternate financing strategies and other options.

22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets

22nd Century (XXII) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About 22nd Century (XXII) Rating Upgrade to Buy

NEW YORK,, Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 22nd Century Group, Inc. ("22nd Century" or the "Company") (NASDAQ: XXII). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 22nd Century Group, Inc. - XXII

Absci Corp

Purple Innovation

Penny stocks are often defined as stocks trading under $5 per share, those with a very low price per share or market capitalization, and are generally higher-risk. Now, despite many such stocks certainly carrying a relatively high risk profile, this often is somewhat offset by higher potential returns.

The 3 Most Undervalued Penny Stocks to Buy Now: August 2023

22nd Century Group Inc (NYSE:XXII) shares tumbled more than 20% after the biotechnology company, which is focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp, cannabis and hops, lowered its full-year revenue guidance. For 2023, the New York-based company now expects sales between $80 to $90 million, below its prior guidance range of $105 to $110 million.

22nd Century shares plunge on slashed revenue guidance

22nd Century Group, Inc. (NASDAQ:XXII ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Matt Kreps - IR Hugh Kinsman - CFO John Miller - Interim CEO Conference Call Participants Vivien Azer - TD Cowen Jim McIlree - Dawson James Operator Good morning, ladies and gentlemen, and welcome to the 22nd Century Group Second Quarter 2023 Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Mr.

22nd Century Group, Inc. (XXII) Q2 2023 Earnings Call Transcript

BUFFALO, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis and hops, today reported results for the Second quarter ended June 30, 2023, and provided an update on recent business highlights. The Company will host a live audio webcast today at 8:00 a.m. ET.

22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results

BUFFALO, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Monday, August 14, 2023, at a revised time of 8:00 AM ET to discuss its 2023 second quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

22nd Century Group (XXII) Updates Second Quarter 2023 Results Webcast Time on August 14, 2023

BUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, will host a live webcast on Monday, August 14, 2023, at 10:00 AM ET to discuss its 2023 first quarter results, which are to be reported in a press release at 6:00 AM ET the same day.

22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023

22nd Century Group's stock price increased by 87% last week, following a 1:15 reverse split in early July; the company's valuation has improved since the split. The company has seen rapid growth following FDA approval of its very low nicotine (VLN) cigarettes and its acquisition of GVB BioPharma. Because of recent volatility, I rate the company as a hold; one should wait for price stabilization before making a long-term investment.

News for 22nd Century Group Stock (XXII)